ABT 894

Product NameABT 894
CAS799279-80-4
MFC10H11Cl2N3
MW244.12
EINECS
MOL File799279-80-4.mol

Chemical Properties

Boiling point	417.4±45.0 °C(Predicted)
Density	1.406±0.06 g/cm3(Predicted)
storage temp.	Store at -20°C
solubility	Soluble in DMSO
form	Solid
pka	10.31±0.20(Predicted)
color	Off-white to brown

Usage And Synthesis

Uses

Sofiniclin (ABT 894), an agonist of nicotinic acetylcholine receptor (nAChR), is used as a potential non-stimulant research for attention-deficit/hyperactivity disorder (ADHD)[1][2].

Biological Activity

Sofiniclin (ABT 894) is an agonist of nAChR as a potential non-stimulatory study in attention deficit disorder.

in vitro

ABT 894 is more potent than ABT-089 at both receptor subtypes, with K _i values of 1.9 nM for ¹²⁵ I-α-conotoxinMII binding and of 1.3 nM for ¹²⁵ I-epibatidine binding.

in vivo

ABT 894 (0.001 to 0.10 mg/kg, po) produces significant reductions in LIDs compared to vehicle monkey. It does not decrease LIDs in monkeys with severe nigrostriatal damage.

< p>

References

[1] Zhang D, et al. ABT-089 and ABT-894 reduce levodopa-induced dyskinesias in a monkey model of Parkinson's disease. Mov Disord. 2014 Apr;29(4):508-17. DOI:10.1002/mds.25817
[2] Zhang D, ET AL. α7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage. Mov Disord. 2015 Dec;30(14):1901-11. DOI:10.1002/mds.26453